FDA NDA: New Drug Application Guide

The New Drug Application (NDA) is the formal regulatory submission through which pharmaceutical sponsors request permission from the United States Food and Drug Administration (FDA) to market a new drug in the United States. Authorized under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and codified in 21 CFR Part 314, the NDA demonstrates that a drug is safe and effective for its proposed indication, its clinical benefits outweigh its risks, and manufacturing methods ensure product identity, strength, and purity.

What it is and who runs it

The FDA NDA regulates commercial marketing of small-molecule pharmaceuticals. Since 1938, every new drug has been the subject of an approved NDA before U.S. commercialization, as the FDA describes it. The documentation in an NDA is meant to tell the whole story of the drug, including clinical test results, ingredients, animal study results, and how the drug behaves in the body and is manufactured.

The primary authority administering NDAs is the FDA Center for Drug Evaluation and Research (CDER). Review divisions within CDER evaluate submissions using multidisciplinary teams across clinical medicine, nonclinical toxicology, clinical pharmacology, biostatistics, and product quality. For development teams, regulatory affairs in the pharmaceutical industry directs how documentation is compiled and managed across agency interactions.

The NDA pathway governs chemical pharmaceuticals, whereas biological products require a Biologics License Application (BLA), as detailed in the NDA vs BLA vs 505(b)(2) vs ANDA comparative guide.

Eligibility (summary, with the official source)

Application content and format are set by 21 CFR § 314.50, as described on the official page on 2026-11-07. Pharmaceutical companies, biotechnology developers, and research institutions may serve as applicants. The FDA describes the NDA as telling the whole story of the drug. Typical supporting evidence falls into three areas:

Nonclinical Pharmacology and Toxicology: Studies under Good Laboratory Practice (21 CFR Part 58), detailing safety pharmacology, pharmacokinetics, and toxicity.
Authorized Clinical Trial Program: Clinical trials conducted under an active Investigational New Drug (IND) application (21 CFR Part 312). Trials must follow Good Clinical Practice guidelines under ICH E6(R3) and documented clinical trial protocol design.
Current Good Manufacturing Practice (cGMP) Readiness: Validated manufacturing, batch controls, and facility readiness under 21 CFR Parts 210 and 211, prepared for FDA pre-approval inspections.

Applicants submit under Section 505(b)(1) for full standalone dossiers or Section 505(b)(2) when relying partly on published literature or prior FDA findings for an approved reference drug.

What it requires

Under 21 CFR § 314.50, an nda submission must be submitted electronically in the Electronic Common Technical Document (eCTD) format across five standardized modules:

Module 1: Administrative Information and Prescribing Information: Administrative forms, including FDA Form 356h, user fee validation under PDUFA, patent listings under 21 CFR § 314.53, debarment statements, and draft labeling.
Module 2: Common Technical Document Summaries: Clinical and nonclinical overviews, the Quality Overall Summary (QOS), and technical summaries of safety and efficacy.
Module 3: Quality (Chemistry, Manufacturing, and Controls): CMC documentation detailing drug substance synthesis, formulation composition, batch release records, packaging systems, analytical methods, and stability data.
Module 4: Nonclinical Study Reports: Complete study reports and raw data for pharmacodynamics, safety pharmacology, pharmacokinetics, genotoxicity, and carcinogenicity.
Module 5: Clinical Study Reports: Clinical study reports for Phase 1 to Phase 3 trials, the Integrated Summary of Safety (ISS), Integrated Summary of Efficacy (ISE), and datasets formatted to CDISC SDTM and ADaM standards.

Application or compliance steps

Executing the new drug application process involves structured milestone interactions with FDA CDER:

Pre-NDA Meeting: Sponsors may hold a pre-NDA meeting with FDA before the application is submitted; the PDUFA goals letter lists it as a meeting held before submission.
eCTD Compilation: The regulatory team compiles all five modules, validates electronic links and leaf definitions against FDA gateway technical standards, and verifies sequence integrity.
Formal Submission: The dossier is transmitted through the FDA Electronic Submissions Gateway (ESG) with Form FDA 356h and confirmed PDUFA user fee payment.
Filing Review Window (Days 0 to 60): Within 60 days of receipt FDA decides whether the application is sufficiently complete to permit a substantive review (21 CFR § 314.101). Around Day 74, FDA sends a letter communicating filing review issues.
Substantive Review and Audits: CDER review teams assess data, issue Information Requests (IRs), and audit trial sites. Quality oversight of contract partners, as outlined in pharmaceutical CRO industry sector operations, is evaluated during site inspections.
Regulatory Action: Review concludes with an approval letter (21 CFR § 314.105) or a complete response letter (21 CFR § 314.110).

Typical timeline phases

The review clock for an nda application is defined by performance commitments under the Prescription Drug User Fee Act (PDUFA), as described in the PDUFA VII goals letter on 2026-11-07. Review goals differ for applications that are not new molecular entities:

Filing Determination Phase (Days 0 to 60): The 60-day period during which CDER determines whether to file the application or issue a Refusal to File (RTF). Around Day 74 FDA communicates filing review issues.
Substantive Review Phase:
- Standard Review: 10 months from the 60-day filing date (12 months from submission) for new molecular entity NDAs under the PDUFA VII goals.
- Priority Review: 6 months from the 60-day filing date (8 months from submission) for priority-designated new molecular entity NDAs.
Mid-Cycle and Late-Cycle Checkpoints: The PDUFA goals letter lists a mid-cycle communication and a late-cycle meeting as interim checkpoints during the review.
Post-CRL Resubmissions: If a CRL is issued, resubmissions are classified as Class 1 (2-month goal) or Class 2 (6-month goal).

Common mistakes

Sponsors encounter operational delays during the fda nda approval process from recurring submission errors:

Refusal to File Actions: Under 21 CFR § 314.101, grounds include no completed application form, an application not in the form required by § 314.50, or an application incomplete on its face.
CMC and Facility Readiness Deficiencies: Inconsistencies between commercial manufacturing scale and clinical batch formulations, unvalidated analytical assays, or unresolved Form FDA 483 findings at manufacturing sites.
Dataset and Traceability Failures: Discrepancies between narrative study reports and electronic datasets, or syntax errors in define.xml files.
Inadequate 505(b)(2) Scientific Bridging: Failure to justify reliance on a listed drug; § 314.101 lists a 505(b)(2) application that duplicates a listed drug and is eligible under 505(j) as a ground for refusal to file.

Related programs

The following table compares marketing authorization pathways administered by FDA CDER and CBER, drawn from 21 CFR and agency documentation, checked 2026-11-07:

Program / Application Type	Governing Authority	Primary Objective	Statutory Framework	Key Difference
Investigational New Drug (IND) Application	FDA CDER / CBER	Exemption to ship unapproved drug for clinical trials	21 CFR Part 312	Pre-marketing authorization; precedes commercial NDA submission
Full New Drug Application (505(b)(1) NDA)	FDA CDER	Full commercial approval of new chemical entities	21 CFR Part 314	Requires complete standalone de novo safety and efficacy dossier
Hybrid New Drug Application (505(b)(2) NDA)	FDA CDER	Commercial approval of modified drugs or new indications	21 CFR Part 314	Allows reliance on published literature or prior FDA findings
Abbreviated New Drug Application (ANDA)	FDA CDER (OGD)	Approval of generic equivalents to listed drugs	21 CFR Part 314 Subpart C	Focuses on bioequivalence without duplicating clinical trials
Biologics License Application (BLA)	FDA CDER / CBER	Approval of therapeutic biologics and vaccines	21 CFR Part 601; PHS Act § 351	Regulates biological products manufactured in living systems

FAQ

What is the difference between an IND and an NDA application?

An Investigational New Drug (IND) application under 21 CFR Part 312 provides regulatory exemption to administer unapproved investigational drugs during clinical trials. An NDA under 21 CFR Part 314 is the formal commercial application submitted after clinical development to obtain legal marketing authorization in the United States.

How does the 505(b)(2) nda submission pathway reduce clinical trial requirements?

The Section 505(b)(2) pathway permits an applicant to rely partly on published literature or prior FDA findings for an approved drug. Under 21 CFR § 314.101, a 505(b)(2) application that duplicates a listed drug and is eligible for submission under 505(j) can be refused for filing.

What triggers an FDA Refusal to File (RTF) during the new drug application process?

Under 21 CFR § 314.101, FDA may refuse to file an application that is incomplete on its face or not in the form required by § 314.50, among other listed grounds. The applicant may request an informal conference in writing within 30 days of certain refusals.

What is the difference between standard and priority review in the fda nda approval process?

Under the PDUFA VII goals, for new molecular entity NDAs, Standard Review targets an action within 10 months of the 60-day filing date (about 12 months from submission) and Priority Review within 6 months of the 60-day filing date (about 8 months from submission).

Sources

U.S. Food and Drug Administration. “New Drug Application (NDA).” Updated 2026. Available at: https://www.fda.gov/drugs/types-applications/new-drug-application-nda (Accessed: 2026-11-07).
Electronic Code of Federal Regulations. “Title 21, Chapter I, Subchapter D, Part 314: Applications for FDA Approval to Market a New Drug.” Available at: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-314 (Accessed: 2026-11-07).
U.S. Food and Drug Administration. “Form FDA 356h: Application to Market a New or Abbreviated New Drug or Biologic for Human Use.” Available at: https://www.fda.gov/about-fda/reports-manuals-forms/forms (Accessed: 2026-11-07).
U.S. Food and Drug Administration Center for Drug Evaluation and Research. “PDUFA Reauthorization Performance Goals and Procedures (PDUFA VII).” Available at: https://www.fda.gov/media/151712/download (Accessed: 2026-11-07).